S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
10 Ways Entrepreneurs Can Navigate a Down Economy
How to Invest in AI's Fast-Growing Market (Ad)
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
How to Invest in AI's Fast-Growing Market (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
PwC Australia sidelines 9 directors as leak of tax information investigated
The Largest Ever Technology Wave Is Coming! (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
10 Ways Entrepreneurs Can Navigate a Down Economy
How to Invest in AI's Fast-Growing Market (Ad)
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
How to Invest in AI's Fast-Growing Market (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
PwC Australia sidelines 9 directors as leak of tax information investigated
The Largest Ever Technology Wave Is Coming! (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
10 Ways Entrepreneurs Can Navigate a Down Economy
How to Invest in AI's Fast-Growing Market (Ad)
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
How to Invest in AI's Fast-Growing Market (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
PwC Australia sidelines 9 directors as leak of tax information investigated
The Largest Ever Technology Wave Is Coming! (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
10 Ways Entrepreneurs Can Navigate a Down Economy
How to Invest in AI's Fast-Growing Market (Ad)
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
How to Invest in AI's Fast-Growing Market (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
PwC Australia sidelines 9 directors as leak of tax information investigated
The Largest Ever Technology Wave Is Coming! (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
NASDAQ:AIMT

Aimmune Therapeutics (AIMT) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$34.49
$34.49
50-Day Range
$34.30
$34.59
52-Week Range
$10.09
$37.00
Volume
N/A
Average Volume
1.71 million shs
Market Capitalization
$2.26 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

AIMT stock logo

About Aimmune Therapeutics (NASDAQ:AIMT) Stock

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow's milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.

Receive AIMT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aimmune Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AIMT Stock News Headlines

The Largest Ever Technology Wave Is Coming!
This summer, a small tech company will launch a key technology to advance artificial intelligence, or AI, that can think, reason and make decisions like humans. It will change the world, just like electricity did.
Aimmune Therapeutics Inc (AIMT)
The Largest Ever Technology Wave Is Coming!
This summer, a small tech company will launch a key technology to advance artificial intelligence, or AI, that can think, reason and make decisions like humans. It will change the world, just like electricity did.
Billionaire Paul Tudor Jones’ Top 5 Stock Picks
AIMT Jan 2023 20.000 put
AIMT Dec 2020 20.000 call
AIMT Jan 2023 22.500 put
AIMT Nov 2020 40.000 put
Nestle Says About 84% Aimmune Shares Tendered
Aimmune Therapeutics (AIMT) Q2 2020 Earnings Call Transcript
Nestle initiates tender offer for Aimmune Therapeutics
See More Headlines

Receive AIMT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aimmune Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AIMT Company Calendar

Last Earnings
7/30/2020
Today
5/29/2023

Industry, Sector and Symbol

Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AIMT
Fax
N/A
Employees
228
Year Founded
N/A

Profitability

Net Income
$-248,500,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.66 per share

Miscellaneous

Free Float
N/A
Market Cap
$2.26 billion
Optionable
Optionable
Beta
1.76

Key Executives

  • Dr. Jayson Donald Alexander Dallas (Age 51)
    Pres, CEO & Director
  • Mr. Eric H. Bjerkholt (Age 59)
    Chief Financial Officer
  • Mr. Douglas T. Sheehy (Age 52)
    Gen. Counsel & Sec.
  • Dr. Stephen George Dilly (Age 59)
    Special Advisor
  • Dr. Daniel C. Adelman (Age 62)
    Chief Medical Officer













AIMT Stock - Frequently Asked Questions

How were Aimmune Therapeutics' earnings last quarter?

Aimmune Therapeutics, Inc. (NASDAQ:AIMT) issued its quarterly earnings data on Thursday, July, 30th. The biotechnology company reported ($1.06) EPS for the quarter, meeting the consensus estimate of ($1.06).

What other stocks do shareholders of Aimmune Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aimmune Therapeutics investors own include Hawkins (HWKN), NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Block (SQ), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Advanced Micro Devices (AMD) and Roku (ROKU).

When did Aimmune Therapeutics IPO?

(AIMT) raised $124 million in an initial public offering on Thursday, August 6th 2015. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Credit Suisse and Piper Jaffray acted as the underwriters for the IPO.

What is Aimmune Therapeutics' stock symbol?

Aimmune Therapeutics trades on the NASDAQ under the ticker symbol "AIMT."

What is Aimmune Therapeutics' stock price today?

One share of AIMT stock can currently be purchased for approximately $34.49.

How much money does Aimmune Therapeutics make?

Aimmune Therapeutics (NASDAQ:AIMT) has a market capitalization of $2.26 billion. The biotechnology company earns $-248,500,000.00 in net income (profit) each year or ($3.97) on an earnings per share basis.

How many employees does Aimmune Therapeutics have?

The company employs 228 workers across the globe.

How can I contact Aimmune Therapeutics?

Aimmune Therapeutics' mailing address is 8000 MARINA BOULEVARD SUITE 300, BRISBANE CA, 94005. The official website for the company is www.aimmune.com. The biotechnology company can be reached via phone at 650-614-5220 or via email at dsheel@aimmune.com.

This page (NASDAQ:AIMT) was last updated on 5/30/2023 by MarketBeat.com Staff

My Account -